JP2015534970A - 多発性骨髄腫の治療のためのアントシアニジン複合体 - Google Patents

多発性骨髄腫の治療のためのアントシアニジン複合体 Download PDF

Info

Publication number
JP2015534970A
JP2015534970A JP2015537264A JP2015537264A JP2015534970A JP 2015534970 A JP2015534970 A JP 2015534970A JP 2015537264 A JP2015537264 A JP 2015537264A JP 2015537264 A JP2015537264 A JP 2015537264A JP 2015534970 A JP2015534970 A JP 2015534970A
Authority
JP
Japan
Prior art keywords
multiple myeloma
complex
delphinidin
cyclodextrin
myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015537264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534970A5 (enExample
Inventor
ノルベルト・レーヴァー
イェンス・ブロシャイト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapiotec GmbH
Original Assignee
Sapiotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapiotec GmbH filed Critical Sapiotec GmbH
Publication of JP2015534970A publication Critical patent/JP2015534970A/ja
Publication of JP2015534970A5 publication Critical patent/JP2015534970A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
JP2015537264A 2012-10-17 2013-10-17 多発性骨髄腫の治療のためのアントシアニジン複合体 Ceased JP2015534970A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12188789 2012-10-17
EP12188789.7 2012-10-17
PCT/EP2013/071779 WO2014060548A1 (de) 2012-10-17 2013-10-17 Anthocyanidin-komplex zur behandlung von multiplem myelom

Publications (2)

Publication Number Publication Date
JP2015534970A true JP2015534970A (ja) 2015-12-07
JP2015534970A5 JP2015534970A5 (enExample) 2016-11-10

Family

ID=47115385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015537264A Ceased JP2015534970A (ja) 2012-10-17 2013-10-17 多発性骨髄腫の治療のためのアントシアニジン複合体

Country Status (8)

Country Link
US (1) US20150258202A1 (enExample)
EP (1) EP2908829A1 (enExample)
JP (1) JP2015534970A (enExample)
KR (1) KR20150070303A (enExample)
CN (1) CN104780925A (enExample)
CA (1) CA2887057A1 (enExample)
HK (1) HK1212590A1 (enExample)
WO (1) WO2014060548A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503416A (ja) * 2012-11-15 2016-02-04 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 消炎性および／または免疫抑制性活性成分としてのデルフィニジン複合体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893883A1 (en) 2012-12-11 2014-06-19 Sapiotec Gmbh Delphinidin for combating melanoma cells
KR102050639B1 (ko) 2017-11-08 2019-11-29 경희대학교 산학협력단 왕불류행 추출물을 포함하는 암의 예방 및 치료용 조성물
KR101982937B1 (ko) 2017-11-08 2019-05-27 경희대학교 산학협력단 천궁 추출물을 포함하는 암의 예방 및 치료용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511513A (ja) * 1992-07-27 1994-12-22 ザ　ユニヴァシティ　オブ　カンサス 水溶性の高いシクロデキストリン誘導体及びその使用
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
JP2005530744A (ja) * 2002-05-04 2005-10-13 サイデックス・インコーポレイテッド アミオダロンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
JP2010539193A (ja) * 2008-04-28 2010-12-16 サイデックス・ファーマシューティカルズ・インコーポレイテッド スルホアルキルエーテルシクロデキストリン組成物
US20110224168A1 (en) * 2010-03-13 2011-09-15 Lajos Szente Fat-binding compositions
JP6081572B2 (ja) * 2012-03-30 2017-02-15 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ アントシアニジン複合体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2235642B2 (es) * 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
RU2013133723A (ru) * 2010-12-31 2015-02-10 Истпонд Лабораториз Лимитед Композиции для клеточной гидратации, содержащие циклодекстрины
US20150051273A1 (en) * 2012-03-30 2015-02-19 Sapiotec Gmbh Use of delphinidin against staphylococcus aureus

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511513A (ja) * 1992-07-27 1994-12-22 ザ　ユニヴァシティ　オブ　カンサス 水溶性の高いシクロデキストリン誘導体及びその使用
JP2005530744A (ja) * 2002-05-04 2005-10-13 サイデックス・インコーポレイテッド アミオダロンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
JP2010539193A (ja) * 2008-04-28 2010-12-16 サイデックス・ファーマシューティカルズ・インコーポレイテッド スルホアルキルエーテルシクロデキストリン組成物
US20110224168A1 (en) * 2010-03-13 2011-09-15 Lajos Szente Fat-binding compositions
JP6081572B2 (ja) * 2012-03-30 2017-02-15 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ アントシアニジン複合体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AICHI-GAKUIN DENT. SCI., vol. 7, JPN6017014721, 1994, pages 27 - 32, ISSN: 0003653775 *
UEDA H, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. V24 N9, JPN5015010856, 1 September 1998 (1998-09-01), US, pages 863 - 867, ISSN: 0003545323 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503416A (ja) * 2012-11-15 2016-02-04 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 消炎性および／または免疫抑制性活性成分としてのデルフィニジン複合体

Also Published As

Publication number Publication date
WO2014060548A1 (de) 2014-04-24
CN104780925A (zh) 2015-07-15
US20150258202A1 (en) 2015-09-17
HK1212590A1 (zh) 2016-06-17
CA2887057A1 (en) 2014-04-24
EP2908829A1 (de) 2015-08-26
KR20150070303A (ko) 2015-06-24

Similar Documents

Publication Publication Date Title
US20240182504A1 (en) Bisphosphonate quinolone conjugates and uses thereof
TW580392B (en) Process for preparing synthetic soil-extract materials and medicaments based thereon
JP2015534970A (ja) 多発性骨髄腫の治療のためのアントシアニジン複合体
CN104016923B (zh) 苯妥英衍生物及其制备方法和用途
AU2017361875A1 (en) Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
JP2023181185A (ja) ビスホスホネート・キノロン複合体及びそれらの用途
JP2017197540A (ja) 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）に対するデルフィニジンの使用
DK2919791T3 (da) Delphinidin-kompleks som antiflogistisk eller immunsuppressivt aktivt stof
RU2443432C2 (ru) Фармацевтическая композиция для введения инъекцией
JP2021532087A (ja) ビスホスホネート・キノロン複合体及びそれらの用途
US9511047B2 (en) Delphinidin for combating melanoma cells
US20250313653A1 (en) Guest/host inclusion complexes containing s-nitrosoglutathione and methods of use thereof
RU2578473C2 (ru) Средство, обладающее противовоспалительной и антиоксидантной активностью
JP2021528499A (ja) 骨標的抗菌オキサゾリジノン関連化合物、その製剤及び用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180227